How is primary biliary cholangitis diagnosed?

Diagnosis of Primary Biliary Cholangitis

Primary biliary cholangitis (PBC) is diagnosed when you have chronic cholestatic liver biochemistry (elevated alkaline phosphatase) plus positive anti-mitochondrial antibodies (AMA) or PBC-specific antinuclear antibodies (anti-gp210 or anti-sp100), after excluding other causes of cholestasis.

Diagnostic Criteria

The diagnosis requires meeting these specific criteria 1:

• Elevated alkaline phosphatase (ALP) - This is the hallmark biochemical finding and must be persistently elevated
• Positive AMA (present in ~95% of cases) with high sensitivity and specificity 2
• OR positive PBC-specific ANAs (anti-gp210 or anti-sp100) if AMA-negative - these have lower sensitivity but very high specificity 2

You need 2 out of 3 criteria: cholestatic biochemistry, positive autoantibodies, and compatible liver histology 1. However, most patients are diagnosed without biopsy when they have the first two.

Step-by-Step Diagnostic Approach

1. Initial Laboratory Testing

Order these specific tests:

• Liver biochemistry panel: ALP is typically elevated 1.5-4x upper limit of normal; GGT parallels ALP elevation
• Transaminases (ALT/AST): Usually mildly elevated (1-2x normal); if markedly elevated (>5x normal), consider overlap syndrome 3
• Bilirubin: Normal in early disease; elevation indicates advanced disease and poor prognosis
• AMA by immunofluorescence or ELISA: Specifically request AMA-M2 subtype for highest specificity 2
• ANA pattern: Look specifically for anti-gp210 and anti-sp100 2
• IgM levels: Elevated in 50-70% of cases 4

2. Exclude Secondary Causes

Before confirming PBC, rule out:

• Biliary obstruction (ultrasound to exclude stones, masses)
• Drug-induced cholestasis (medication history)
• Other autoimmune liver diseases
• Primary sclerosing cholangitis (MRCP if IBD present or atypical features)

3. When to Perform Liver Biopsy

Biopsy is NOT routinely needed when ALP is elevated and AMA is positive 1.

DO perform biopsy in these specific situations 3, 1:

• AMA-negative disease with positive PBC-specific ANAs or unexplained cholestasis
• Suspected overlap syndrome: AST/ALT >5x normal, IgG elevated, or positive smooth muscle antibodies
• Atypical presentation: Normal ALP despite positive AMA (rare phenotype) 5
• Prognostic staging when treatment decisions depend on fibrosis stage

4. Imaging Requirements

• Abdominal ultrasound: Perform initially to exclude biliary obstruction, assess for cirrhosis complications 1
• MRCP: Only if features suggest PSC (IBD, young age, male sex, or atypical cholangiographic pattern suspected) 3
• Do NOT routinely image bile ducts in typical PBC presentation

Atypical Presentations Requiring Expanded Testing

AMA-Negative PBC (~5% of cases)

When ALP is elevated but AMA is negative 5, 2:

1. Test for anti-gp210 and anti-sp100 (positive in 30-50% of AMA-negative cases)
2. Consider anti-hexokinase 1 and anti-KLHL12 (emerging markers for seronegative cases) 2
3. Liver biopsy is mandatory to confirm diagnosis - look for chronic non-suppurative destructive cholangitis 6

Normal ALP with Positive AMA

This rare phenotype exists 5:

• Use GGT as alternative cholestatic marker - may be elevated when ALP is normal
• Monitor closely as disease may evolve
• Consider biopsy for confirmation and staging

Common Diagnostic Pitfalls

Avoid these errors:

• Don't dismiss mildly elevated ALP (1.5x normal) with positive AMA - this IS diagnostic
• Don't assume PSC just because patient has IBD - 60-80% of PSC has IBD, but PBC can coexist with IBD too
• Don't delay diagnosis waiting for symptoms - most patients are asymptomatic at diagnosis 4
• Don't confuse with PSC: PBC has positive AMA, affects small ducts, and MRCP is normal; PSC has negative AMA, affects large ducts, and MRCP shows beading 7

Overlap Syndromes

Suspect PBC/AIH overlap when 3:

• AST or ALT >5x upper limit of normal
• IgG elevated >1.3x normal
• Positive smooth muscle antibodies or high-titer ANA (>1:320)
• Biopsy showing moderate-to-severe interface hepatitis is required for overlap diagnosis 3

This matters because overlap syndromes require immunosuppression in addition to ursodeoxycholic acid 3.

Prognostic Assessment at Diagnosis

Once diagnosed, immediately assess:

• Bilirubin level: Elevated bilirubin indicates advanced disease
• Platelet count and albumin: Low values suggest cirrhosis
• Presence of anti-gp210: Associated with more aggressive disease and progression to liver failure 2
• Presence of anti-centromere antibodies: Associated with portal hypertension and worse prognosis 2

Start ursodeoxycholic acid immediately at 13-15 mg/kg/day - don't wait for staging 4, 1.